Opko Health, Inc. (NASDAQ:OPK) CEO Phillip Md Et Al Frost acquired 260,000 shares of Opko Health stock in a transaction on Thursday, September 14th. The shares were purchased at an average cost of $5.98 per share, for a total transaction of $1,554,800.00. Following the acquisition, the chief executive officer now owns 3,068,951 shares in the company, valued at approximately $18,352,326.98. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Phillip Md Et Al Frost also recently made the following trade(s):

  • On Friday, August 25th, Phillip Md Et Al Frost purchased 25,000 shares of Opko Health stock. The stock was bought at an average cost of $6.17 per share, for a total transaction of $154,250.00.
  • On Thursday, August 24th, Phillip Md Et Al Frost purchased 10,000 shares of Opko Health stock. The stock was bought at an average cost of $6.24 per share, for a total transaction of $62,400.00.
  • On Wednesday, August 23rd, Phillip Md Et Al Frost acquired 12,000 shares of Opko Health stock. The shares were acquired at an average cost of $6.13 per share, for a total transaction of $73,560.00.
  • On Tuesday, August 22nd, Phillip Md Et Al Frost acquired 1,800 shares of Opko Health stock. The shares were acquired at an average cost of $6.13 per share, for a total transaction of $11,034.00.
  • On Monday, August 21st, Phillip Md Et Al Frost acquired 25,000 shares of Opko Health stock. The shares were acquired at an average cost of $6.10 per share, for a total transaction of $152,500.00.
  • On Thursday, August 17th, Phillip Md Et Al Frost acquired 50,000 shares of Opko Health stock. The shares were acquired at an average cost of $5.96 per share, for a total transaction of $298,000.00.
  • On Wednesday, August 16th, Phillip Md Et Al Frost acquired 40,000 shares of Opko Health stock. The shares were acquired at an average cost of $6.04 per share, for a total transaction of $241,600.00.
  • On Tuesday, August 15th, Phillip Md Et Al Frost acquired 25,000 shares of Opko Health stock. The shares were acquired at an average cost of $6.08 per share, for a total transaction of $152,000.00.
  • On Monday, August 14th, Phillip Md Et Al Frost acquired 10,000 shares of Opko Health stock. The shares were acquired at an average cost of $6.15 per share, for a total transaction of $61,500.00.
  • On Friday, August 11th, Phillip Md Et Al Frost acquired 10,000 shares of Opko Health stock. The shares were acquired at an average cost of $6.19 per share, for a total transaction of $61,900.00.

Shares of Opko Health, Inc. (NASDAQ:OPK) traded up 0.083% during midday trading on Friday, reaching $6.025. 994,842 shares of the company’s stock traded hands. The stock has a 50-day moving average price of $6.22 and a 200 day moving average price of $6.90. Opko Health, Inc. has a 12 month low of $5.85 and a 12 month high of $12.15. The firm’s market cap is $3.37 billion.

Opko Health (NASDAQ:OPK) last released its earnings results on Tuesday, August 8th. The biotechnology company reported ($0.04) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.05) by $0.01. Opko Health had a negative net margin of 6.52% and a negative return on equity of 3.67%. The firm had revenue of $314.20 million during the quarter, compared to the consensus estimate of $322.64 million. During the same period in the prior year, the firm earned $0.02 EPS. The company’s revenue was down 12.0% compared to the same quarter last year. Equities research analysts predict that Opko Health, Inc. will post ($0.19) earnings per share for the current year.

COPYRIGHT VIOLATION WARNING: This article was posted by American Banking News and is owned by of American Banking News. If you are viewing this article on another website, it was illegally stolen and republished in violation of United States and international copyright & trademark law. The correct version of this article can be read at https://www.americanbankingnews.com/2017/09/15/opko-health-inc-opk-ceo-purchases-1554800-00-in-stock.html.

Several hedge funds have recently made changes to their positions in OPK. Capstone Asset Management Co. lifted its stake in shares of Opko Health by 8.6% during the 1st quarter. Capstone Asset Management Co. now owns 17,646 shares of the biotechnology company’s stock valued at $141,000 after buying an additional 1,400 shares in the last quarter. Shell Asset Management Co. purchased a new stake in Opko Health in the 1st quarter worth approximately $551,000. Wells Fargo & Company MN lifted its stake in Opko Health by 70.8% in the 1st quarter. Wells Fargo & Company MN now owns 699,650 shares of the biotechnology company’s stock worth $5,597,000 after purchasing an additional 290,084 shares in the last quarter. Canada Pension Plan Investment Board purchased a new stake in Opko Health in the 1st quarter worth approximately $2,197,000. Finally, Advisors Asset Management Inc. lifted its stake in Opko Health by 305.1% in the 1st quarter. Advisors Asset Management Inc. now owns 32,661 shares of the biotechnology company’s stock worth $261,000 after purchasing an additional 24,599 shares in the last quarter. Institutional investors own 22.46% of the company’s stock.

OPK has been the subject of a number of research reports. J P Morgan Chase & Co cut Opko Health from an “overweight” rating to a “neutral” rating and lowered their target price for the stock from $12.00 to $7.00 in a report on Thursday. Cantor Fitzgerald initiated coverage on Opko Health in a report on Thursday, August 17th. They issued an “overweight” rating and a $20.00 price objective for the company. Zacks Investment Research cut Opko Health from a “buy” rating to a “hold” rating in a report on Saturday, August 12th. Jefferies Group LLC restated a “hold” rating and issued a $6.50 price objective (down previously from $6.80) on shares of Opko Health in a report on Thursday, August 10th. Finally, BidaskClub cut Opko Health from a “hold” rating to a “sell” rating in a report on Tuesday, August 1st. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and six have given a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and an average price target of $14.36.

Opko Health Company Profile

OPKO Health, Inc is a healthcare company. Its segments include Pharmaceutical, Diagnostics and Corporate. Pharmaceutical consists of the pharmaceutical operations in Chile, Mexico, Ireland, Israel and Spain and its pharmaceutical research and development operations. Diagnostics consists of the clinical laboratory operations in Bio-Reference Laboratories (Bio-Reference) and its point-of-care operations.

Insider Buying and Selling by Quarter for Opko Health (NASDAQ:OPK)

Receive News & Ratings for Opko Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opko Health Inc. and related companies with MarketBeat.com's FREE daily email newsletter.